Working… Menu

Safety and Efficacy Study of Eribulin in Combination With Bevacizumab for Second-line Treatment HER2- MBC Patients (GIM11-BERGI)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT02175446
Recruitment Status : Unknown
Verified June 2016 by Consorzio Oncotech.
Recruitment status was:  Recruiting
First Posted : June 26, 2014
Last Update Posted : June 15, 2016
Clinical Research Technology S.r.l.
Information provided by (Responsible Party):
Consorzio Oncotech

No Study Results Posted on for this Study
Recruitment Status : Unknown
Estimated Primary Completion Date : December 2016
Estimated Study Completion Date : December 2017
Publications of Results:

Other Publications:
Cohen A, et al. Clinical outcomes in Bevacizumab (BV)-treated patients (pts) with metastatic colorectal cancer (mCRC): Results from ARIES observational cohort study (OCS) and confirmation of BRITE data on BV beyond progression (BBP). ASCO 2010
Saab TB, et al. Bevacizumab (BV) plus chemotherapy (CT) in 2nd line metastatic colorectal cancer (mCRC): Initial results from ARIES a second observational cohort study. ASCO 2010.